LifeTech Scientific
Market Cap
HK$9.7b
Last Updated
2020/08/05 13:08 UTC
Data Sources
Company Financials +
Executive Summary
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders.
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with limited growth.
Share Price & News
How has LifeTech Scientific's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1302's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
0.4%
1302
2.8%
HK Medical Equipment
2.3%
HK Market
1 Year Return
62.6%
1302
235.1%
HK Medical Equipment
6.9%
HK Market
Return vs Industry: 1302 underperformed the Hong Kong Medical Equipment industry which returned 222.6% over the past year.
Return vs Market: 1302 exceeded the Hong Kong Market which returned 6% over the past year.
Shareholder returns
| 1302 | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.4% | 2.8% | 2.3% |
| 30 Day | -9.2% | 6.9% | -2.2% |
| 90 Day | 26.3% | 56.7% | 10.6% |
| 1 Year | 62.6%62.6% | 237.2%235.1% | 11.3%6.9% |
| 3 Year | 34.5%34.5% | 208.6%200.0% | 1.8%-9.1% |
| 5 Year | 51.7%51.7% | 312.5%293.3% | 14.3%-4.8% |
Price Volatility Vs. Market
How volatile is LifeTech Scientific's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
What You Need To Know About LifeTech Scientific Corporation's (HKG:1302) Investor Composition4 weeks ago | Simply Wall St
LifeTech Scientific Corporation's (HKG:1302) Price In Tune With Earnings1 month ago | Simply Wall St
A Look At The Fair Value Of LifeTech Scientific Corporation (HKG:1302)Valuation
Is LifeTech Scientific undervalued compared to its fair value and its price relative to the market?
65.16x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 1302 (HK$2.26) is trading above our estimate of fair value (HK$2.14)
Significantly Below Fair Value: 1302 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 1302 is poor value based on its PE Ratio (65.2x) compared to the HK Medical Equipment industry average (50.8x).
PE vs Market: 1302 is poor value based on its PE Ratio (65.2x) compared to the Hong Kong market (10.4x).
Price to Earnings Growth Ratio
PEG Ratio: 1302 is poor value based on its PEG Ratio (4.1x)
Price to Book Ratio
PB vs Industry: 1302 is overvalued based on its PB Ratio (7.6x) compared to the HK Medical Equipment industry average (4.1x).
Next Steps
Future Growth
How is LifeTech Scientific forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
15.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1302's forecast earnings growth (15.7% per year) is above the savings rate (1.6%).
Earnings vs Market: 1302's earnings (15.7% per year) are forecast to grow slower than the Hong Kong market (18.2% per year).
High Growth Earnings: 1302's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1302's revenue (19.9% per year) is forecast to grow faster than the Hong Kong market (11.3% per year).
High Growth Revenue: 1302's revenue (19.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1302's Return on Equity is forecast to be low in 3 years time (14%).
Next Steps
Past Performance
How has LifeTech Scientific performed over the past 5 years?
28.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1302 has high quality earnings.
Growing Profit Margin: 1302's current net profit margins (19.3%) are lower than last year (21.8%).
Past Earnings Growth Analysis
Earnings Trend: 1302 has become profitable over the past 5 years, growing earnings by 28.7% per year.
Accelerating Growth: 1302's earnings growth over the past year (6.7%) is below its 5-year average (28.7% per year).
Earnings vs Industry: 1302 earnings growth over the past year (6.7%) underperformed the Medical Equipment industry 16%.
Return on Equity
High ROE: 1302's Return on Equity (10.9%) is considered low.
Next Steps
Financial Health
How is LifeTech Scientific's financial position?
Financial Position Analysis
Short Term Liabilities: 1302's short term assets (CN¥605.8M) exceed its short term liabilities (CN¥341.2M).
Long Term Liabilities: 1302's short term assets (CN¥605.8M) exceed its long term liabilities (CN¥269.3M).
Debt to Equity History and Analysis
Debt Level: 1302's debt to equity ratio (28.4%) is considered satisfactory.
Reducing Debt: 1302's debt to equity ratio has reduced from 51% to 28.4% over the past 5 years.
Debt Coverage: 1302's debt is well covered by operating cash flow (83.3%).
Interest Coverage: 1302's interest payments on its debt are well covered by EBIT (10.3x coverage).
Balance Sheet
Next Steps
Dividend
What is LifeTech Scientific current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1302's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1302's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1302's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1302's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 1302 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1302's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.9yrs
Average board tenure
CEO
Yuehui Xie (51 yo)
5.42yrs
Tenure
CN¥16,254,000
Compensation
Mr. Yuehui Xie has been the Chief Executive Officer at LifeTech Scientific Corporation since March 2, 2015. Mr. Xie is responsible for overall strategic planning and management of LifeTech Scientific Corpo ...
CEO Compensation Analysis
Compensation vs Market: Yuehui's total compensation ($USD2.33M) is above average for companies of similar size in the Hong Kong market ($USD565.26K).
Compensation vs Earnings: Yuehui's compensation has been consistent with company performance over the past year.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 5.42yrs | CN¥16.25m | 18.07% CN¥ 1.8b | |
| CFO, Executive VP | 5.42yrs | CN¥12.99m | 0.19% CN¥ 18.2m | |
| Independent Non-Executive Director | 8.83yrs | CN¥108.00k | no data | |
| Independent Non-Executive Director | 6.33yrs | CN¥108.00k | no data | |
| Non-Executive Director | 6.33yrs | CN¥108.00k | no data | |
| Independent Non-Executive Director | 4.58yrs | CN¥108.00k | no data | |
| Non-Executive Director | 1yr | no data | no data |
5.9yrs
Average Tenure
51yo
Average Age
Experienced Board: 1302's board of directors are considered experienced (5.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
LifeTech Scientific Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: LifeTech Scientific Corporation
- Ticker: 1302
- Exchange: SEHK
- Founded: 1999
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: HK$9.690b
- Shares outstanding: 4.33b
- Website: https://www.lifetechmed.com
Number of Employees
Location
- LifeTech Scientific Corporation
- Cybio Electronic Building
- Langshan 2nd Street
- Shenzhen
- Guangdong Province
- 518057
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 1302 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Common Shares | HK | HKD | Nov 2011 |
| 1302 | SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect) | Yes | Common Shares | HK | HKD | Nov 2011 |
Biography
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The c ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/08/05 13:08 |
| End of Day Share Price | 2020/08/05 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.